MOTS-c.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015. MOTS-c is research / preclinical, and PepCue grades its published evidence F tier (30/100). This is a research reference, not medical or dosing advice.
What it is
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome, first described around 2015. It belongs to a small family of "mitochondrial-derived peptides" that appear to act as metabolic signaling molecules. It is an investigational research compound, not an approved drug, and is frequently grouped with longevity peptides where hype tends to outrun the evidence.
How it works
In preclinical models MOTS-c is described as a stress-responsive signaling peptide: it has been reported to activate the AMPK energy-sensing pathway and to influence folate and methionine (one-carbon) metabolism, and under metabolic stress it can translocate to the cell nucleus where it is proposed to help regulate adaptive, antioxidant gene expression. These mechanisms are largely characterized in cell and animal systems; how faithfully they translate to a clinical effect in people is not established.
Mechanism pathways
Mitochondria-derived and mitochondria-targeted peptides in metabolism and stress responses.
Mitochondria are not only the site of oxidative phosphorylation; they are also signalling organelles that communicate their status to the rest of the cell and, through circulating factors, to the rest of the body. Two distinct classes of peptide are grouped here, and the distinction matters because they are quite different things. The first class is peptides encoded within mitochondrial DNA itself, in short open reading frames inside genes normally read as ribosomal RNA. These are genuinely mitochondria-derived and act as signalling molecules. One has been described as a stress-responsive regulator that activates the AMP-activated protein kinase energy-sensing pathway, influences folate and methionine one-carbon metabolism, and under metabolic stress translocates to the cell nucleus where it is proposed to help direct adaptive antioxidant gene expression. Another acts both inside and outside the cell: intracellularly it binds and antagonises pro-apoptotic Bcl-2 family proteins, preventing their translocation to mitochondria and suppressing programmed cell death, and extracellularly it signals through a cytokine-like receptor complex that activates STAT3 and engages formyl peptide receptors. It also interacts with insulin and IGF-1 signalling. Circulating levels of both have been described as declining with age, which is the observation driving interest in them. The second class is not mitochondria-derived but mitochondria-targeted by design. A peptide with an alternating aromatic and cationic motif carries a net positive charge that drives selective accumulation in the inner mitochondrial membrane, where it binds reversibly to cardiolipin, an anionic phospholipid found almost exclusively there. By associating with cardiolipin it is proposed to stabilise cristae architecture, protect the interaction between cardiolipin and cytochrome c, and support electron-transport-chain organisation and membrane potential. This is a structural stabilisation mechanism rather than a receptor-mediated signal, and it is why the compound is described as improving mitochondrial efficiency rather than stimulating it. Honest assessment: this is an active and legitimate research field with well-characterised molecular interactions, but the characterisation is predominantly in cell and animal systems. Human clinical evidence is limited, and the mitochondria-targeted compound has been through clinical trials in specific conditions without producing a clearly positive result in every setting. None of these is an approved medicine, and none should be described as an established treatment for age-related decline or metabolic disease.
The evidence
The evidence base is predominantly preclinical. The foundational study (Lee et al., Cell Metabolism, 2015) reported that MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance in mice, and later work has linked it to exercise physiology and measured circulating levels in humans as a biomarker. However, there are no controlled human trials demonstrating that administering MOTS-c produces a meaningful clinical benefit. The gap between the animal/mechanistic data and proven human outcomes is large and should not be glossed over.
The evidence, in brief
A mitochondrial-derived peptide studied for metabolism and exercise biology. Research is predominantly preclinical (cell and animal models). No approved therapeutic use and essentially no human outcome trials; among the more hype-prone longevity peptides.
- Lee C et al.: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceCell Metab, 2015 (PMID 25738459)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #044
Mostly preclinical or mechanistic; little human data.
Findings come mainly from animal models, not people.
Claim receipts
Popular claims about MOTS-c, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Mitochondrial and metabolic effects are mainly preclinical; human evidence is minimal.
Safety profile
Human safety is essentially uncharacterized. There are no published human toxicology, long-term, or drug-interaction data for administered MOTS-c. As an injectable compound sold research-use-only, the purity, identity, and sterility of non-pharmaceutical material are additional unknowns on top of the absent clinical safety package. It should be regarded as an experimental compound of unknown human risk.
Compound notes
- MOTS-c is a mitochondrial-derived peptide, a short peptide encoded within the mitochondrial 12S rRNA gene.
- It is studied as a regulator of metabolic homeostasis and insulin sensitivity, sometimes described as an “exercise-mimetic” signal in animal models.
- Evidence is mainly preclinical; human data is minimal.
- Not FDA-approved; research-only.
- “Reverses aging / boosts metabolism” claims rest on animal work, not human outcomes.
Regulatory status
MOTS-c is not approved by the FDA (or any major regulator) for any indication and is not a recognized dietary supplement; it is an investigational, research-use-only compound with no registered human therapeutic trials.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01A mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region, described around 2015
- 02Proposed to act through AMPK and one-carbon (folate/methionine) metabolism in preclinical models
- 03The foundational evidence is a 2015 mouse study showing improved metabolic homeostasis and reduced insulin resistance
- 04Studied in humans mainly as an exercise-responsive biomarker, not in controlled treatment trials
- 05No published human safety, pharmacokinetic, or efficacy data for administered MOTS-c
- 06Not FDA-approved; sold research-use-only and among the more hype-prone longevity peptides
MOTS-c: research formats
Choose the format you are researching to see route-specific notes.
Mitochondrial peptide; SC is most common. Some research uses IM for larger volumes.
MOTS-c is sold as a 5–10 mg vial. Reconstituting 10 mg with 2.0 mL BAC water gives 5,000 mcg/mL, a dense solution. Because studied doses in publications are in the low-mg range, injection volumes can be moderate.
Sources
Every factual claim above resolves to a real, published source.
- Lee C et al.: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceCell Metab, 2015 (PMID 25738459)
- Mitochondrial-derived peptides (MOTS-c) and exercise/metabolism: peer-reviewed literaturePubMed / NCBI
Cite this page
PepCue. “MOTS-c: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/mots-c.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.